Agile Medical Countermeasure Decision Support Tool (AMDST) Prototype

Purpose

This solicitation, issued by MTEC, represents a Request for Project Proposals (RPP) for MTEC in support of the U.S. Defense Threat Reduction Agency (DTRA). Military relevance is a critical component of the Enhanced White Paper submission. Strategic oversight for the award(s) supported by this RPP will be provided by DTRA’s Chemical and Biological Technologies Department (RD-CB) in its role as the Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense Program (CBDP).

This RPP is focused on the development of a software prototype that will allow a medical planner to assess the residual operational risk for a mission after layering in threat risk, medical countermeasure (MCM) risk-benefit tradeoffs, and fielding risk during mission planning. The Agile Medical Countermeasure Decision Support Tool (AMDST) layering model is intended to include all MCMs for a potential threat, including FDA-approved, repurposed, and investigational drugs. One of the goals for AMDST is to make operational planners aware of MCMs in the investigational and repurposed drug pipeline, allowing a demand signal from operations for MCM interim fielding.

Scope of Work

Objective:

The objective of this effort is to develop a decision support software prototype [AMDST] to enable users with a range of expertise to compare operationally relevant risks and benefits of layered MCM plans. AMDST shall facilitate:

• Timely assessment and examination of various layered MCM courses of action (COAs).
• Analysis of risk-benefit tradeoffs during mission planning with CB threat potential.
• Allowing a user with limited to no medical knowledge to compare COAs and, as needed, send a demand signal for specific investigational or repurposed MCMs up-the-chain of command.
• Provide visualizations of residual risk scores among a set of candidate COAs for the planner to display to a decision maker for MCM planning in response to a mission.

Note: The scope of a COA will be limited to pre-planning, staging, and deployment of different MCMs to the battlefield in support of the mission and not on the administration of MCMs into an individual warfighter.

Points of Contact

For inquiries, please direct your correspondence to Biomedical Research Associate Chuck Hutti, Ph.D. at Chuck.Hutti@ati.org.